Arcus Biosciences Debt
RCUS Stock | USD 9.34 0.20 2.10% |
Arcus Biosciences holds a debt-to-equity ratio of 0.17. At this time, Arcus Biosciences' Short Term Debt is comparatively stable compared to the past year. Short and Long Term Debt Total is likely to gain to about 49.8 M in 2025, whereas Long Term Debt is likely to drop slightly above 38.4 M in 2025. . Arcus Biosciences' financial risk is the risk to Arcus Biosciences stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Arcus Biosciences' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Arcus Biosciences' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Arcus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Arcus Biosciences' stakeholders.
For most companies, including Arcus Biosciences, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Arcus Biosciences, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Arcus Biosciences' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Total Current Liabilities is likely to drop to about 115.9 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 822.9 M in 2025Arcus |
Arcus Biosciences Bond Ratings
Arcus Biosciences financial ratings play a critical role in determining how much Arcus Biosciences have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Arcus Biosciences' borrowing costs.Piotroski F Score | 4 | Poor | View |
Beneish M Score | (2.14) | Possible Manipulator | View |
Arcus Biosciences Debt to Cash Allocation
Many companies such as Arcus Biosciences, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Arcus Biosciences currently holds 48 M in liabilities with Debt to Equity (D/E) ratio of 0.17, which may suggest the company is not taking enough advantage from borrowing. Arcus Biosciences has a current ratio of 6.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Arcus Biosciences' use of debt, we should always consider it together with its cash and equity.Arcus Biosciences Total Assets Over Time
Arcus Biosciences Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Arcus Biosciences uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Arcus Biosciences Debt Ratio | 5.15 |
Arcus Biosciences Corporate Bonds Issued
Arcus Net Debt
Net Debt |
|
Understaning Arcus Biosciences Use of Financial Leverage
Arcus Biosciences' financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Arcus Biosciences' current equity. If creditors own a majority of Arcus Biosciences' assets, the company is considered highly leveraged. Understanding the composition and structure of Arcus Biosciences' outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Net Debt | -102 M | -107.1 M | |
Short Term Debt | 12.7 M | 18 M | |
Short and Long Term Debt Total | 48 M | 49.8 M | |
Long Term Debt | 43.2 M | 38.4 M | |
Net Debt To EBITDA | 0.38 | 0.36 | |
Debt To Equity | 0.10 | 0.08 | |
Interest Debt Per Share | 0.58 | 0.61 | |
Debt To Assets | 0.04 | 0.05 | |
Long Term Debt To Capitalization | 0.08 | 0.07 | |
Total Debt To Capitalization | 0.09 | 0.07 | |
Debt Equity Ratio | 0.10 | 0.08 | |
Debt Ratio | 0.04 | 0.05 | |
Cash Flow To Debt Ratio | (3.54) | (3.72) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.